

## Personal Information

---

**Name:** Dr. Shahnaz Sali

**About me:**



In-depth leading knowledge of viral hepatitis and liver diseases, tuberculosis, antibiotic stewardship, and nosocomial infections. Hands-on practical medical skills in liver biopsy and other infectious diseases, as well as experience in the management of the training department at Tehran Social Security Organization. Successfully completed many management training courses. Keen to elaborate on such issues as acute and chronic liver diseases, particularly viral hepatitis diagnosis and management, and to investigate pulmonary and extrapulmonary tuberculosis. Has been an active reviewer for reputable local and international journals. Achieved top 10 reviewer status (4th position) for Hepatitis Monthly Journal and serves as an active reviewer for the Archives of Clinical Infectious Diseases Journal (ARCHCID). Quite skilled in general and medical computer software.

**Work Address:** Labbafinejad Hospital, 9th Boostan, Pasdaran St, Tehran, Iran

**Work Tel/fax:** +98-21-22546026

**Email Address:** [dr.shsali@gmail.com](mailto:dr.shsali@gmail.com)

[sh.sali@sbmu.ac.ir](mailto:sh.sali@sbmu.ac.ir)

**Date of Birth:** 06 September 1968

**Place of Birth:** Arak, Iran

**Marital Status:** Married, one son

**Special Interest:** Carrying research and compose medical / scientific papers

**Current Position:** **Professor of Infectious Diseases**, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

## Education

---

**1986-1993** **General Practitioner** - Shahid Beheshti University of Medical Sciences, Tehran, Iran.

**1993-1997** **Infectious Diseases Specialist** - Shahid Beheshti University of Medical Sciences, Tehran, Iran.

**1994-1995** **MPH** - Tehran University of Medical Sciences, Tehran, Iran.

**2010** **Research and Clinical Observer** - Barts and The London School of Medicine, London, United Kingdom.

## Status

---

<b>2022 Jan - Present</b>	<b>Professor</b> of Infectious Diseases, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
<b>2016 July- 2022 January</b>	<b>Associate Professor</b> of Infectious Diseases, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
<b>2011 Sept – 2016 July</b>	<b>Assistant Professor</b> of Infectious Diseases, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
<b>2004- Present</b>	<b>Member</b> of the Infectious Disease and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

## Affiliation(s)

---

<b>2001 - Present</b>	<b>Member</b> of Tehran Hepatitis Center.
<b>2011 - Present</b>	<b>Member</b> of Global Hepatitis Network.
<b>2007 - Present</b>	<b>Active Reviewer</b> - Hepatitis Monthly Journal
<b>2012 - Present</b>	<b>Active Reviewer</b> - Archives of Clinical Infectious Diseases Journal
<b>2012 - Present</b>	<b>Active Reviewer</b> - Novelty in Biomedicine Journal

## Work Experience

---

<b>1997 - 2005</b>	<b>Infectious Disease Specialist - Hepatitis B Consultant, Social Security of Iran.</b> <ul style="list-style-type: none"><li>✓ Receiving patients with infectious Disease Complaints.</li><li>✓ Providing Consultation to liver disease-related patients.</li><li>✓ Carrying out Liver Biopsies for patients with liver-related diseases.</li><li>✓ Giving consultation to families who may have a liver-related disease.</li><li>✓ Managed to bring together records and some statistics of patients with</li></ul>
<b>2005 - 2010</b>	<b>Training Manager- Social Security of Tehran Province, Tehran, Iran.</b> <ul style="list-style-type: none"><li>✓ Design and implement “on-the-job training” for Medical Doctors, Managers, Supervisors, and other higher-ranked personnel of Tehran Province Social Security.</li><li>✓ Evaluate and assess personnel receiving on-the-job training and issue performance certificates.</li><li>✓ Design and implement various specialty workshops for various groups of personnel.</li></ul>

**2000 - 2010**

**Infectious Diseases Consultant- Milad Specialized Hospital, Tehran, Iran.**

- ✓ Providing consultation to various wards.
- ✓ Attending daily outpatient clinics and visiting patients.
- ✓ Providing specialized consultation for liver diseases and viral hepatitis and carrying out liver biopsies, where applicable.

**1993 - 1997**

**Medical Resident- Shahid Labbafinejad Hospital, an affiliate of Shahid Beheshti University of Medical Sciences.**

- ✓ Being in charge of the Infectious Disease Ward during different working shifts.
- ✓ Supervising Stagers and other university students receiving training.
- ✓ Visiting admitted patients at the Infectious Diseases Ward.
- ✓ Providing Infectious Diseases Consultation to different wards.
- ✓ Visiting patients at the outpatient Department.

**Achievements**

---

**Gained invaluable experience in the management of illness.**

**Developed my skills in the preparation of papers and research reports.**

**Top Researcher at the 6<sup>th</sup> Research Festival of Shahid Beheshti University of Medical Sciences (2005)**

**Oral Papers Presented:**

---

1. "Some Cases of Misdiagnosis of Hepatitis"; The 8th Iranian Congress on Infectious Disease and Tropical Medicine, January 2000.
2. "Handling HCV Patients"; The 8th Iranian Congress on Infectious Disease and Tropical Medicine, January 2000.
3. "Approach to Chronic HBV and HCV"; Re-training Seminar on Hepatitis, Karaj District, Iran, November 2000.
4. "Thalassemia Profile with HCV Infection"; Hepatitis and Special Diseases Seminar, February 2001.
5. "Reviewing Hepatitis B and C Virus in Karaj City"; Hepatitis, Prophylaxis and Treatment Seminar, November 2001.
6. "Indication and Complication of Liver Biopsy in Chronic Viral Hepatitis in Karaj"; Chronic Hepatitis, Prophylaxis and Treatment Seminar, July 2002.
7. "Relation between Laboratory Test Result and Histological Hepatitis Activity in Individuals with Hepatitis C Virus"; The 13th Iranian Congress on Infectious Disease and Tropical Medicine, December 2004.
8. "Prediction of Liver Histological lesions with Biochemical In-Patients with Chronic Hepatitis B"; The 13th Iranian Congress on Infectious Disease and Tropical Medicine, December 2004.

9. "Chronic HBV and need for Patients Education Program (PEP)"; Review of Latest Viral Hepatitis Patients Management. December 2005.
10. "Prediction value of Histological Activity induced with LFT and viral load in Chronic Hepatitis B"; The 14th Iranian Congress on Infectious Disease and Tropical Medicine, January 2006.
11. "Levamisole does not enhance protective Ab response to HBV vaccination in hemodialysis patients' population with a high response rate to routine vaccination"; IDRC Shahid Beheshti University of Medical Sciences, December 2006.
12. "Prevention and transmission of viral Hepatitis"; Milad Hospital, Viral Hepatitis Seminar, November 2006.
13. "Effect of Levamisole on HBV Vaccine in Hemodialysis Patients", International Internal Medicine Congress, December 2008.
14. "Effect of HBV genetic diversity on outcome and prognosis chronic hepatitis B", 3rd Tehran Hepatitis Congress, 2010.
15. "Survival Of Chronic HBV In Iran", 4th Tehran Hepatitis Congress, Nov 2011.
16. "Association Of IL28 B Polymorphism and HCV Core70 Amino Acid Substitution in Chronic Hepatitis C Patients", 4th Tehran Hepatitis Congress, Nov 2011.
17. "Chronic Hepatitis C, Genotype, Metabolic Disorder and BMI: An Iranian Case Series", 5th Tehran Hepatitis Congress, May 2013.
18. "HBV Vaccine Escape Mutation Among Family Members of Chronic Hepatitis B", 5th Tehran Hepatitis Congress, May 2013.
19. "The Role of Serum HBsAg Concentration and HBV DNA Level in Clinical", 5th Tehran Hepatitis Congress, May 2013.
20. "Approach to Chronic HBV", 6th Tehran Hepatitis Congress, April 2015.
21. "CVC Infection in HD, Diagnosis & Management Infection in Hemodialysis and Kidney Transplantation Congress, Feb 2015.
22. Viral Hepatitis in Hemodialysis and Kidney Transplantation, International Urology and Nephrology Congress, Jul 2015.
23. Outpatient and inpatient treatments for COVID-19 and cutaneous complications of COVID-19 Seminar, May 2022
24. "Preventive approach after needle exposure with patients suffering from hepatitis C", 8<sup>th</sup> Tehran Hepatitis Conference, August 2022
25. "Immunology of viral diseases", The 16th International Congress of Immunology and Allergy, April 2023
26. "Hepatitis B: A practical approach, prevention challenges for new treatment", 9<sup>th</sup> Tehran Hepatitis Conference, September 2023
27. "Challenges of simultaneous treatment of hepatitis and HIV", 10<sup>th</sup> Tehran Hepatitis Conference, June 2024
28. "Clinical symptoms and complications of dengue fever", dengue fever conference, July 2024
29. "Care and treatment of hepatitis B disease", Methods of diagnosis and treatment of viral hepatitis, July 2024

30. "Clinical manifestations and diagnosis of dengue fever" Reviewing Infectious and Viral Diseases Seminar (dengue fever - coronavirus - influenza), September 2024
31. New developments and challenges in liver diseases, October 2024
32. "Methods of preventing influenza", Influenza disease and an overview of avian influenza, November 2024
33. "Treatment of brucellosis in special cases" The 9th Congress on Brucellosis, November 2024
34. "Prevention of Chickenpox in Women of Childbearing Age and Management of Chickenpox During Pregnancy", Chickenpox: Clinical symptoms, vaccination, and prevention, August 2025
35. "Hepatitis A: Risks, Prevention, and Challenges in Vulnerable Populations", 11<sup>th</sup> Tehran Hepatitis Conference, June 2025
36. The 9<sup>th</sup> National Congress on AIDS, December 2025

## Published Papers

---

1. "Reviewing Hepatitis C and Handling the Patients"; Review Article, The Islamic Republic of Iran Medical Authorities Magazine, December 2000.
2. "Interferon  $\alpha_2b$  (PD feron B) in Treatment of HBeAg- Chronic Hepatitis B"; Hepatitis Monthly, Vol. 4, June 2004.
3. "Risk factors in chronic Hepatitis B infection" Hepatitis Monthly, 5(4):109-115.2006
4. "HBV Vaccination in Chronic Renal Failure Patients" Hepatitis Monthly, 6(1):25-29.2006
5. Effect of levamisole supplementation on hepatitis B virus vaccination response in hemodialysis patients. Nephrology. 2008;13(5):376-9.
6. "Real Response to therapy in Chronic Hepatitis C Virus Patients: A Study from Iran"; Hepatitis Monthly. 2012 12(9): e6151.
7. "A rare case presentation of oral actinomycosis", Iranian Journal of Mycobacteriology, June 2013.
8. "HIV and Viral Hepatitis (B, D, C) Co-Infection, Genotyping, Epidemiological Profile in West of Tehran"; Sextrans, May 2013. doi:10.1136/sextrans-2013-051184.0673
9. "Influencing Factors on the Outcome and Prognosis of Patients with HBV Infection: Seven Years Follow-up"; Hepatitis Monthly. 2013 Jul; 13(7): e8743.
10. "Occupational Exposure to Blood Borne Viruses Among Healthcare Workers in a Tertiary Care Referral Hospital in Tehran"; Hepatitis Monthly. 2013 Jul; 13(7): e12201.
11. "Non-Invasive Histologic Markers of Liver Disease in Patients with Chronic Hepatitis B"; Hepatitis Mon. 2014 February; 14(2): e14228.
12. "Can Serum Level of HBsAg Differentiate HBeAg-negative Chronic Hepatitis B from Inactive Carrier State?"; Diagnostic Microbiology and Infectious Diseases. 2015 February; in press.
13. "An Unusual Presentation of Tuberculous Meningitis"; Arch Clin Infect Dis. 2015 July; 10(3): e26083.
14. "Seroclearance of HBs Ag in Chronic Hepatitis B Virus Patients on Lamivudine Therapy: A 10 Year Experience"; Global Journal of Health Science; Vol. 7, No. 6; 2015.

15. Can serum level of hepatitis B surface antigen (HBsAg) differentiate HBsAg inactive carrier state from chronic hepatitis B? *Journal of Hepatology*. 2015(62):S539.
16. "Multiple Intracranial Tuberculomas in a Post-Kidney Transplant Patient"; *Saudi J Kidney Dis Transpl* 2016;27(1):135-138.
17. "Association of Plasma Levels of Vitamin D With Chronic Hepatitis B Infection"; *Hepat Mon*. 2016 January; 16(1): e35525.
18. "Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review- Screened"; *Hepat Mon*. 2016 April; 16(4):e35810.
19. "Tumor Necrosis Factor 308 G/A Polymorphisms and Risk of Hepatocellular Carcinoma: A Meta-Analysis"; *Hepat Mon*. 2016 April; 16(4): e33537.
20. "Outcome of Accidental Exposure Prone to Blood Borne Viral Infections in an Educational Hospital"; *Novelty in Biomedicine*, Received: 15 November, 2015; Accepted: 11 January, 2016.
21. "Manipulation of Regulatory Cells' Responses to Treatments for Chronic Hepatitis B Virus Infection"; *Hepat Mon*. In Press (In Press): e37927.
22. "A case of endocarditis presenting with icterus"; *Sch J Med Case Rep* 2016; 4(6):404-408.
23. "Seroprevalence of Hepatitis A in Hemodialysis Patient Candidates for Kidney Transplant Younger Than Forty Years", *Novelty in Biomedicine*, 5(2),49-53.
24. Tumor necrosis factor- $\alpha$ -308 G/A polymorphisms and risk of hepatocellular carcinoma: A meta-analysis. *Hepatitis Monthly*. 2016;16(4):e33537.
25. "Assessment of Risk Factors in Patients with Chronic Hepatitis B Referred to Dr. Labbafinejad Hospital Hepatitis Clinic 2012-2014", *Novelty in Biomedicine*, 5(1),37-42
26. "Comparison of Vitamin D Levels in Naive, Treated, and Inactive Carriers with Chronic Hepatitis B Virus", *Journal of Clinical and Translational Hepatology* 2016 vol. 4 | 306–309
27. "Assessment of the Human Cytomegalovirus UL97 Gene to identify the Resistance to Ganciclovir in Kidney Transplant Recipients in Labbafinejad Hospital", *Int J Infect*. (In press):e41189.
28. Outcome of Inactive Carriers of HBV in 10 Years Follow-Up in Iran. *RESEARCH JOURNAL OF PHARMACEUTICAL BIOLOGICAL AND CHEMICAL SCIENCES*. 2016;7(4):1390-5.
29. "Uncommon Transmission of HIV Infection Due to a Criminal Knife Fight", *Case Reports in Clinical Practice Journal*, VOL 2, NO 1, Winter 2017.
30. "Incidence and Resistance Patterns of Nosocomial Infections in Labbafinejad Hospital Admitted Patients during 2012-2014", *Infect Epidemiol Microbiol*. 2017 Summer; Volume 3, Issue 3: 78-81.
31. "Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: Lessons learned from nucleus(t)ide analogues therapy", *Immunology Letters*, Volume 190 October 2017, Pages 206-212.
32. "The Sustained Virologic Response and Adverse Effects of Peg Interferon Alfa and Ribavirin in the Treatment of Patients with Chronic Hepatitis C: A Study from Iran", 2017 *Novelty in Biomedicine*, 5 (4), 17355-17355.
33. "Chronic Hepatitis C, Genotyping, Metabolic Status and Body Mass Index in Iranian Population", *Journal of Clinical Gastroenterology and Hepatology*, Vol.2 No.1:3,2018.

34. "A Forty-Four-Year-Old Immunized Woman with Maculopapular and Petechial Rash, Diagnosed as Measles: An Extremely Rare Presentation", *Int J Infect*. 2018 April; 5(2):e69070.
35. "Skin Necrosis After Ketorolac Intravascular Administration" 2018 Case Report in *Clinical Practice J*. 3(3)P:86-9
36. "Isolated Retrobulbar Hydatid Cyst: A Case Report" *Novelty in Biomedicine* 2018;6(1):51-4.
37. "A 44 -Year-Old Immunized Woman with Maculopapular and Petechial Rash, Diagnosed as Measles: AN Extremely Rare Presentation, *International J Infectious*, Published online 2018 April 16.
38. SD1000: 96.4 SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran-a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients. *Journal of Viral Hepatitis*. 2018;25:198-9.
39. "Phylogenetic Analysis of Hepatitis B Virus among Household Members with HBV Chronic Infection", *Avicenna J Med Biotech* 2019; 11(3): 221-228
40. "Viral Load And Nucleotide Substitutions in Hepatitis B Viruses Derived from Chronic HBV Patients" 2019 *Mediterranean Journal of Hematology and Infectious Diseases*; 11(1)
41. "A Young Immunocompetent Cytomegalovirus Retinitis Patient" *Novelty in Biomedicine*, 2019;7(1):35-7.
42. "SD1000: High Sustained Viral Response Rate in 1361 patients with hepatitis C genotypes 1, 2, 3, and 4 using a low-cost fixed-dose combination tablet generic sofosbuvir and ..." 2019 *Clinical Infectious Diseases*,
43. "Journal of Clinical and Translational Hepatology" 2019 *Journal of Clinical and Translational Hepatology*
44. "Tenofovir Response Rate and Adverse Effects in Patients with Chronic Hepatitis B Attending to Hepatitis Clinic at Labbafinejad Hospital" 2019 *Jundishapur Journal of Natural Pharmaceutical Products*, 14 (3)
45. "Comparing the efficacy and safety of treating chronic hepatitis B infection during pregnancy with lamivudine, telbivudine, and tenofovir: a meta-analysis" 2019 *Journal of Clinical and Translational Hepatology*
46. Tenofovir Alafenamide: A New Drug With Various Ambiguous Aspects in Treatment of Chronic Hepatitis B Infection. *Archives of Clinical Infectious Diseases*. 2019;14(14):e84569.
47. "Daclatasvir/sofosbuvir versus ledipasvir/sofosbuvir in patients with HCV infection genotypes 1, 3. 2020 *Novelty in Biomedicine*
48. "Efficacy and Tolerability of Daclatasvir/Sofosbuvir (Datex) in Patients with HIV-HCV Co-infection", 2020, *Archives of Clinical Infectious Diseases*, 15 (3)
49. "Evaluation of the efficacy of arbidol in comparison with the standard treatment regimen of hospitalized patients with COVID-19: a randomized clinical trial", 2020, *Archives of Clinical Infectious Diseases*, 15 (5)
50. Evaluation of symptoms, radiological findings, laboratory data and outcome in COVID-19 patients with chronic kidney disease at Tehran, Iran. 2020.

51. "SD1000: high sustained viral response rate in 1361 patients with hepatitis C genotypes 1, 2, 3, and 4 using a low-cost, fixed-dose combination tablet of generic sofosbuvir and ...", 2020, *Clinical Infectious Diseases*
52. "COVID-19 and kidney transplant recipients", 2020, *Transplant Infectious Disease*
53. "Epidemiology, Clinical and Laboratory Manifestations, and Outcomes of Brucellosis Among 104 Patients in Referral Hospitals of Tehran, Iran", 2021 *Archives of Clinical Infectious Diseases*, 16 (2)
54. "Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients with Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic ...", 2021, *Clinical Infectious Diseases*
55. "Single-pill sofosbuvir and daclatasvir for treating hepatitis C in patients co-infected with human immunodeficiency virus", 2021, *International Journal of Clinical Practice*, e14304
56. "Impact of COVID-19 on 75 Immunocompromised Patients: Does Immunosuppression Alter the Clinical Course?", 2021, *Infection Epidemiology and Microbiology*
57. "Anti-tuberculosis Induced Stevens-Johnson Syndrome Due to Misdiagnosis of Mycobacterium Abscessus Urinary Tract Infection as Tuberculosis", 2021, *Iranian Journal of Kidney Diseases*
58. "Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study" 2020, *Transfusion and Apheresis Science: official journal of the World Apheresis Association: official journal of the European Society for Hemapheresis*, 59(5):102875
59. "An investigation into the Effects of Intravenous Vitamin C on Pulmonary CT Findings and Clinical Outcomes of Patients with COVID-19 Pneumonia A Randomized Clinical Trial" 2021 *Urology journal*, :6863
60. "Assessment of agents and resistant patterns of nosocomial urinary tract infection by epsilometer test (e-test) method in a tertiary hospital" 2021 *Journal of Isfahan Medical School*, 39(629), pp. 451-455
61. "Sofosbuvir for the Treatment of COVID-19 Patients: Is It a Promising Therapeutic Medicine for the Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2?" *Avicenna J Med Biochem*. 2020;8(2): 133-135.
62. "Diagnosis of Toxoplasma Infection in Allogenic Pre-HCTSP Patients Using Molecular Methods" 2022 / Original Article *Iranian Journal of Parasitology*, 17(2), pp. 231-239.
63. "The Importance of Screening Strongyloides stercoralis Infection in Solid Organ Transplant Donors and Recipients" 2021 / Original Article *Archives of Clinical Infectious Diseases*, 16(4), e118047
64. Descriptive Analysis of COVID-19 among Health Care Workers in a Tertiary Center in Iran. *Tanaffos*. 2021;20(3):246-52.
65. Effects of Adding Convalescent Plasma Therapy for Treatment of COVID-19 Patients with Severe and Critical Symptoms: a Descriptive Study of 12 Cases. *Novelty in Biomedicine*. 2021;9(2):39.
66. Comparison of the Efficacy of Sofosbuvir and Kaletra on the Outcome of COVID-19. Is Sofosbuvir A Potential Treatment For COVID-19? *Novelty in Biomedicine*. 2021;9(1):17-23.

67. Evaluation of the Clinical, Laboratory and Imaging Findings of Patients with COVID-19 and Their Associations with Clinical Outcomes in an Iranian Hospital: A Cross-Sectional Study. *Novelty in Biomedicine*. 2021;9(4):165-70.
68. “Comparing Efficacy and Safety of Piperacillin/tazobactam and Amoxicillin/clavulanic acid in the Treatment of Complicated Urinary Tract Infections”. 2022; *Novelty in Biomedicine* 10 (3)
69. “Bromhexine, for post-exposure COVID-19 prophylaxis: A Randomized, Double-Blind, Placebo Control Trial’ *Jundishapur Journal of Microbiology* 15(8),e130198
70. “Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial.” *Vaccine*. 2024;42(9):2254-9.
71. “Mapping antimicrobial susceptibility of community-acquired uropathogenic *Escherichia coli* across low, middle and high-income countries highlights significant differences: insights for empiric treatment.” *IJID Reg*. 2025;16:100706.
72. Efficacy and safety of ketorolac and dexamethasone for preventing renal colic post stent removal: a randomized triple-blind, placebo-controlled clinical trial. *Annals of Medicine and Surgery*. 2025;87(2):565-70.

### General Practitioner’s Thesis Supervisor

---

1. Economical estimation of Streptococcal pharyngitis and strategic analysis for determining its diagnosis and treatment in Iran. *Vahid Shahkarami*, 2013.
2. Epidemiology, clinical and laboratory manifestations & outcome of patients with brucellosis admitted to subordinate hospitals of Shahid Beheshti University of Medical Sciences during 1394 to 1399
3. Survey of Etiology of Infectious Diseases in Elderly Patients Admitted to the Infectious Ward of Labbafinejad Hospital in 2017 and 2018
4. Serum Level of Protective Hepatitis B Antibody in Medical Students Entered Shahid Beheshti University in 2014-2015.
5. The Immunity and Prevalence of COVID-19 among physicians and health care workers at Labbafinejad Hospital and treatment of asymptomatic carriers
6. Evaluation of the causes of death in COVID-19 hospitalized patients at the infection ward of Shahid Doctor Labbafinejad Hospital in 2020
7. Evaluation of characteristics of dead patients from hospitalized COVID-19 patients at Labbafinejad Hospital during 1399
8. The effect of Sofosbuvir/Daclatasvir on HIV infection in patients with chronic hepatitis C during 2017-2018

1. Phylogenic intra familial analysis of HBV amongst Labbafinejad Hospital Outpatient Clinic. Shirin Azarmanesh, 2010-2011.
2. The outcome of HBV inactive carrier state amongst Iranian patients in a 10 years period. Zahra Seghatoleslam, 2013.
3. Investigating mutation related to Gancyclovir resistance within UL 97 of CMV amongst Iranian kidney transplantation infected with CMV under Gancyclovir therapy at Labbafinejad Hospital, Farhad Soori, 2012.
4. Investigation on antibiotic resistance pattern and bacterial infection risk factors amongst kidney transplant patients at Labbafinejad Hospital during 2014 and 2015, Marjan Hemmatian.
5. Investigating distribution of risk factors of chronic hepatitis C among patients visiting Labbafinejad Hospital during 2014 and 2015, Marziyeh Ashrafi Chalan Olia.
6. Evaluating 53 cases of HBV Cirrhosis at Labbafinejad Hospital, Farazam Quicky, 2015.
7. Consideration of antibiotic-resistant pattern and risk factors of bacterial infection in kidney transplant patients in Labbafinejad hospital during 2013-2014, Marjan Hematian, 2015.
8. Vit D3 level in different stages if chronic hepatitis B, Baharan Farkhondemehr, 2016.
9. Tenofovir response rate and adverse effects in patients with chronic hepatitis B attending the hepatitis clinic 2017, M. Nassiri
10. Evaluation of symptoms, radiological findings, laboratory data and outcome in COVID-19 patients with chronic kidney disease at Tehran, Iran
11. The sustained virologic response and adverse effects of peg interferon and ribavirin in the treatment of patients with chronic hepatitis C referring to labbafinejad hospital in 2014-2016 M.Laali
12. Assessment of immunity against hepatitis A in positive HIV patients referred to Loghman Hakim Hospital from 2020 to 2021. N.Koosha
13. Determining genotype of the dominant organism in catheter-related infection in hemodialysis patients and assessment of antibiotic resistance using E-TEST L.Soleimani

## Training Courses/Workshops

---

- |  |  |
|--|--|
| 1. Introduction to ISO- 10015 (Training); TUV Academy.                         | 8. Evaluation Management.  |
| 2. Internal Quality Audit based on Requirements of ISO 9000:2000; TUV Academy. | 9. Management Information Systems.   |
| 3. Strategic Management.   | 10. Management of Health Centers and Organizations.  |
| 4. Problem Solving.  | 11. Research Workshop: Techniques for the preparation of Proposals, Advanced Methodology and Search Strategy, etc. |
| 5. Human Resources.  |  |
| 6. Stress Management.  |  |
| 7. Change Management.  | 12. SPSS Application   |

## Professional Courses/Workshops

---

1. Lesson Plans.
2. Teaching Methods.
3. Clinical Teaching.
4. Student Evaluation Techniques.
5. Professional Ethics.
6. Terminology in Medical Education.

## Published Books

---

1. Chronic Viral Hepatitis C; Summer 2002
2. Practical Approach to Viral hepatitis; Summer 2015.
3. Guide for Managers of Care and Treatment of Viral Hepatitis B, C, D (Hepatitis C Elimination Program), Spring 2025